Previously published data on YM-155 sensitivity of a large panel of cancer cell lines indicated that resistance may also be associated with low SLC35F2 expression, therefore before moving onto in vivo testing expression of this efficacy biomarker could be studied within chondrosarcoma spheroids (Winter et al., 2014). The gene discussed is SLC35F2; the disease is chondrosarcoma.